



Capital increase in connection with exercise of warrants

In December 2013, Ambu A/S issued 2,000,000 warrants, in December 2014 2,000,000 warrants and in December 2015 770,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 52 individuals participate in the 2013 scheme, 22 individuals participate in the 2014-scheme and 46 individuals participate in the 2015 scheme. In all cases, the vesting period is three years, and all schemes can therefore be exercised in the trading window that opened on 1 May 2019 in connection with Ambu's interim financial report for Q2 2018/19.

Since 1 May 2019, instructions have been received to exercise warrants as follows:

- 2013 scheme: One individual has issued instructions to exercise a total of 50,000 warrants at the agreed exercise price of DKK 13.26 per share with a nominal value of DKK 0.50.
- 2014 scheme: One individual has issued instructions to exercise a total of 50,000 warrants at the agreed exercise price of DKK 23.06 per share with a nominal value of DKK 0.50.
- 2015 scheme: Six individuals have issued instructions to exercise a total of 120,000 warrants at the agreed exercise price of DKK 39.26 per share with a nominal value of DKK 0.50.

Today Ambu's Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 110,000 from DKK 125,754,800 to DKK 125,864,800 through the issue of 220,000 Class B shares.

Following this and in consideration of the employees having left the company, there are 50,000 remaining warrants under the 2013 scheme being held by three individuals, 550,000 remaining warrants under the 2014 scheme being held by seven individuals and 450,000 remaining warrants under the 2015 scheme being held by 28 individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 15 May 2019 under the ISIN code of Ambu A/S' existing B shares (DK0060946788).

Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

	Number of shares (nominal value DKK 0.50)	Nominal value (DKK)	Voting rights
A shares	34,320,000	17,160,000	343,200,000
B shares	217,409,600	108,704,800	217,409,600
Total	251,729,600	125,864,800	560,609,600

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

Ambu A/S
Baltorpbakken 13
2750 Ballerup, Denmark
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.ambu.com

About Ambu

Since 1937, breakthrough ideas have fuelled our work on bringing efficient healthcare solutions to life. This is what we create within our fields of excellence – Visualisation, Anaesthesia, and Patient Monitoring & Diagnostics. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of our products. We are dedicated to improve patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ resuscitator and the legendary BlueSensor™ electrodes to our newest landmark solutions like the Ambu aScope™ – the world's first single-use flexible endoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognized medtech companies in the world. Headquartered near Copenhagen in Denmark, Ambu employs approximately 2,700 people in Europe, North America and the Asia Pacific. For more information, please visit www.ambu.com.